Viratech Corp. (VIRA)

[Deleted123]

$VIRA DD Updated:

85 mil float confirmed with TA 3 times in the past week.


Common Stock Outstanding: 754,143,750 (as of 9/30/2015)
Restricted Common Stock: 668,687,689(as of 9/30/2015)
Preferred Stock Outstanding: 3,882,500 (as of 9/30/2015)

FLOAT: 85,456,061


600 mil of the OS is owned by the execs so we can be sure they won't RS as it would hurt them too much.

- Selling books on Amazon( $AMZN )
- Have medical software that they announced is out of R&D and ready to be contracted and licensed
- A new CEO who was brought on board at the end of August to get this product out to companies.
- ZERO and I mean ZERO convertible notes/diluters.

Company Headquarters
429 W. Plumb Lane
Reno, NV 89509
Phone: [phone]
Email:
Website: www.viratech.org

Website works great and was updated recently.

Transfer Agent:
Standard Registrar and Transfer Co.
12528 S. 1840 E.
Draper UT 84020
801-571-8844

Here you can see $VIRA volume for the past few months... suddenly picks up 9/25




$VIRA chart



Kevin Buckman, MD
Person Named above owns 600,000,000 shares of Common Stock and 3,500,000 shares of
Preferred Stock.
Kevin Buckman, President, owns 79.56% of its Common Stock

Valerie Kidd Bishop, Treasurer
Person Named above owns 1,850,000 shares of Common stock.

VIRATECH CORP ANNOUNCES THAT FRED SCHIEMANN HAS JOINED VIRATECH AS ITS NEW CEO

RENO, NEVADA /August 25, 2015 –Viratech, Corp. (OTC: VIRA), a software company focusing on developing disruptor based applications in the communication broadcasting, work flow management, crowd sourced labor and biotechnology fields. Viratech announced today that Fred Schiemann has joined Viratech as its new CEO.

Mr. Schiemann received his Bachelor of Science degree in accounting from the University of Illinois. He received his MS in Taxation from Golden Gate University. He currently is licensed as a Certified Public Accountant in Nevada.
“Viratech has now completed an extended phase of research and development for its proprietary software platform. The Company can now enter into the execution of business development agreements with entities looking to fully execute on our revenue sources available utilizing our proprietary software platform. I am excited that we have someone of Fred Schiemann’s experience as our new CEO,” stated Kevin Buckman former Viratech CEO and current Viratech Chief Medical Officer.
Mr. Schiemann has experience in the natural resource business, renewable energy, health sciences/medical, telecommunications and numerous other industries. He has experience in the investor relations industry and has numerous contacts in the broker/dealer community.
During his years of practice, his main areas of focus have been taxation, auditing and public securities work. He has been involved with many public registrations and structuring of mergers and acquisitions over the last twenty plus years. His emphasis is on public registrations, administration and consulting to small and micro-cap public companies.
Mr. Schiemann has assisted in the completion dozens of public offerings through reverse mergers and/or acquisitions, providing the necessary documentation for compliance as required by the regulatory agencies. His guidance and experience has helped companies raise millions of dollars in capital and he has built a reputation as a trusted professional.


From this news you can see that their next focus is revenues, acquisitions and new mergers!


VIRATECH CORP ANNOUNCES THAT DR.KEVIN BUCKMAN HAS BECOME ITS NEW CHIEF MEDICAL OFFICER



RENO, NEVADA /August 25, 2015 –Viratech, Corp. (OTC: VIRA), is a software company focusing on developing disruptor based applications in the communication broadcasting, work flow management, crowd sourced labor and biotechnology fields. The Company announced today that Kevin Buckman MD has become its new CMO (Chief Medical Officer). Dr. Buckman previously served as CEO of Viratech Corp.

“Four years ago Dr. Buckman had a vision in creating a software platform that could capture, interact and broadcast information in a unique way. Now that the computer software infrastructure is built, I am excited that Dr. Buckman will be our Chief Medical Officer in charge of all new Biotech applications of our new software platform” stated Fred Schiemann, Viratech’s new Chief Executive Officer.

Kevin Buckman MD, is a best-selling author on cancer, diabetes and cellular metabolism. He has over thirty nine years of Health Care Experience in a variety of areas of medicine, including research, diagnosis, and application of current medicine and other procedures. Dr. Buckman has presented research, published articles and books in the field of medicine, and has given lectures at numerous hospitals and at Medical Conferences in many different countries.

During the last thirty five years, he has worked to advance a number of medical technologies with a focus on Non-Harmful early detection of disease, with a primary focus on Breast Cancer, Diabetes and other auto-immune diseases. He is currently serving on the Industry Advisory Board for the University of Pacific School of Engineering and Computer Science and a Visiting Professor. He has decades of hospital Medical Director experience and has served on over many hospital committees for thirty five years and has served as Medical Director or Associate Director at Multiple Institutions.